PEŘINA, Vojtěch, Richard SALZMAN and Jana TREGLEROVÁ. Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management. ENT-EAR NOSE & THROAT JOURNAL. THOUSAND OAKS: SAGE PUBLICATIONS INC, 2024, vol. 103, No 5, p. 277-281. ISSN 0145-5613. Available from: https://dx.doi.org/10.1177/01455613211053389.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management
Authors PEŘINA, Vojtěch (203 Czech Republic, belonging to the institution), Richard SALZMAN (703 Slovakia) and Jana TREGLEROVÁ (203 Czech Republic, belonging to the institution).
Edition ENT-EAR NOSE & THROAT JOURNAL, THOUSAND OAKS, SAGE PUBLICATIONS INC, 2024, 0145-5613.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30206 Otorhinolaryngology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.300 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1177/01455613211053389
UT WoS 000710707200001
Keywords in English osteonecrosis; surgical treatment; denosomab; auditory canal; ear
Tags 14110227, auditory canal, denosomab, ear, osteonecrosis, rivok, surgical treatment
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 12/7/2024 12:56.
Abstract
Background: Antiresorptive drugs are widely used to reduce bone mineral loss in patients with osteoporosis and to prevent skeletal-related events in patients with metastatic cancers and multiple myeloma (MM). Both the bisphosphonates (BP) and denosumab typically used in this indication were shown to be effective and relatively safe. Obviously, this medication could have some adverse effects; one of them is osteonecrosis of the external auditory canal. Only sporadic cases of external auditory canal osteonecrosis have been published yet. Here, we provide a case of denosumab-related osteonecrosis of the external auditory canal successfully treated surgically in the early stage of the disease. Case report: A 68-year-old patient with breast cancer underwent comprehensive oncological treatment, including denosumab administration. She was diagnosed with osteonecroses in the jaw and ear canal. The necrotic bones in both regions were resected with primary wound closure. Both affected sites healed well with no signs of necrosis recurrence. Conclusions: Osteonecrosis of the external auditory canal is a rare but probably underdiagnosed complication of antiresorptive medication. It has a negative impact on patient quality of life if left untreated. Early surgical treatment appears to be effective. The authors highlight several similarities with medication-related osteonecrosis of the jaw. Therefore, an analogous disease staging and treatment rationale is suggested.
PrintDisplayed: 21/7/2024 08:26